Sarah Dayre Appointed Guerbet Senior VP, Technical Operations: Effective February 1, 2021

Northwell Health Ranked Nation’s Top Health System for Diversity

New York State’s largest health care provider and private employer made the list for the ninth straight year and remained in the top spot in the 2021 DiversityInc rankings for Hospitals and Health Systems.

ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

Kathy Sherwood Joins Pelvital USA, Inc. Board of Directors

Sherwood's experience, which includes a diverse group of medical product companies such as Boston Scientific, American Medical Systems, St. Jude Medical, Kinetic Concepts, Transoma Medical and Medtronic, gives her an understanding of the problems faced by both large and small companies.

January 28, 2021

Sarah Dayre will report directly to David Hale, CEO of Guerbet*.

Sarah Dayre is a Doctor of Pharmacy and a graduate of ENSIC in France (Process engineering).

She has gained over 20 years’ experience of pharmaceutical manufacturing and the global supply chain working for AstraZeneca in Europe and Asia.

In 2017 Sarah Dayre was appointed head of operations of the Wuxi site in China, in charge of regional and global markets.

“Sarah is a leader with extensive pharmaceutical expertise and I’m delighted to welcome her to our Executive Committee, where she will play a key role in helping us to meet the ambitious organizational efficiency targets set for our industrial operations, required to achieve our transformation,” said David Hale.

*Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles